- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Elotuzumab Combo Delays Myeloma Progression in Phase 3 Trial
A presscast held prior to the annual meeting of the American Society of Clincal Oncology presented interim results from the phase 3 ELOQUENT-2 trial. Adding elotuzumab to lenalidomide and dexamethasone reduced the risk of disease progression by 30% in patients with relapsed-refractory multiple myeloma.
Adding elotuzumab to lenalidomide (Revlimid) and dexamethasone reduced the risk of disease progression by 30% in patients with relapsed-refractory multiple myeloma (RRMM), according to interim results from the phase 3 ELOQUENT-2 trial. The data, which were presented during a presscast held in advance of the 2015 annual meeting of the American Society of Clinical Oncology (ASCO), showed that combining the monoclonal antibody with standard care prolonged remission by 4.5 months.
“Based on this randomized phase 3 trial, we hope that we will soon have a new treatment option for patients with relapsed or refractory myeloma where an immune therapy—based approach can be added with lenalidomide and dexamethasone for the management of these patients,” said lead author Sagar Lonial, MD, chief medical officer of the Winship Cancer Institute of Emory University, and professor and executive vice chair o the department of hematology and medical oncology of Emory University School of Medicine.
Elotuzumab, which is being developed by Bristol-Myers Squibb and AbbVie, binds to the SLAMF7 protein found on the surface of both myeloma cells and natural killer lymphocytes in the immune system. “One of the unique attributes of elotuzumab is that it appears to have a dual mechanism through which it both targets the myeloma cell and appears to enhance the activation of natural killer cells,” said Lonial.
Read more at OncLive.
Accountable Care Organizations and HPV Vaccine Uptake: A Multilevel Analysis
October 24th 2024The authors evaluated whether adolescents receiving care at accountable care organizations (ACOs) vs non-ACOs were more likely to initiate and complete the human papillomavirus (HPV) vaccination series.
Read More
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Hospital Stays and Probable Dementia as Predictors of Relocation to Long-Term Care Facilities
October 22nd 2024This article explores late-life relocations in patients with dementia, hospital stays, and their implications for health care policy, geriatric care, and future research priorities.
Read More
Cost Savings From an mHealth Tool for Improving Medication Adherence
October 21st 2024The Wellth smartphone app significantly increased medication adherence and lowered unnecessary health care utilization and costs over 9 months among Medicaid beneficiaries who were self-managing chronic conditions.
Read More
